Advertisement

An Alternative Approach to Drug Treatment in Psychiatry

  • Joanna Moncrieff
Chapter

Abstract

This article explores an alternative understanding of how psychiatric drugs work that is referred to as the “drug-centred” model of drug action. Unlike the standard “disease-centred” model, which suggests that psychiatric drugs work by correcting an underlying brain abnormality, the drug-centred model emphasises how psychiatric drugs affect mental states and behaviour by modifying normal brain processes. The alterations produced are superimposed on the emotional and behavioural problems that constitute the symptoms of mental disorders. The chapter examines research into drug action to show the dearth of support for the disease-centred model. It then explores the clinical implications of adopting a drug-centred model of drug action. This requires a detailed understanding of the mental and physical alterations produced by individual drugs and an exploration of how those alterations might interact with particular sets of symptoms and problems. Drug-centred approaches to the drug treatment of psychosis and depression are presented as examples. It is concluded that any benefits due to being in an altered state need to be carefully balanced against the damage that may occur with long-term exposure and that we need further research to elucidate all the consequences of using drugs in this way.

Keywords

Psychopharmacology Antipsychotics Antidepressants Models of drug action 

References

  1. 1.
    Abse DW, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. Am J Psychiatr. 1960;116:973–80. Available from: PM:13791594CrossRefGoogle Scholar
  2. 2.
    Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v haloperidol plus promethazine. Br J Psychiatry. 2004;185:63–9. Available from: PM:15231557CrossRefGoogle Scholar
  3. 3.
    American Psychiatric Association. Lets talk facts about depression. Ref type: pamphlet. Washington, DC; 2005.Google Scholar
  4. 4.
    Berridge CW. Neural substrates of psychostimulant-induced arousal. Neuropsychopharmacology. 2006;31(11):2332–40. Available from: PM:16855535CrossRefGoogle Scholar
  5. 5.
    Bourin M, Fiocco AJ, Clenet F. How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol. 2001;16(1):9–21. Available from: PM:12404593CrossRefGoogle Scholar
  6. 6.
    Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res. 1982;7(1):69–81. Available from: PM:6813888CrossRefGoogle Scholar
  7. 7.
    Breggin P. Brain-disabling treatments in psychiatry. 2nd ed. New York: Springer Publishing Company; 2008.Google Scholar
  8. 8.
    Casey JF, Bennett IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Arch Gen Psychiatry. 1960a;2:210–20. Available from: PM:13808145CrossRefGoogle Scholar
  9. 9.
    Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatr. 1960b;117:97–105. Available from: PM:13808146CrossRefGoogle Scholar
  10. 10.
    Chouinard G. The use of benzodiazepines in the treatment of manic-depressive illness. J Clin Psychiatry. 1988;49(Suppl):15–20. Available from: PM:2903143PubMedGoogle Scholar
  11. 11.
    Dubovsky SL, Davies R, Dubovsky AN. Mood Disorders. In: Hales RE, Yudofsky SC, editors. Textbook of clinical psychiatry. Washington, DC: American Psychiatric Association; 2001.Google Scholar
  12. 12.
    Eli Lilly. (2006) Zyprexa website. www.zyprexa.com/bipolar/treating.asp. 7-12-2006. Ref type: electronic citation.
  13. 13.
    Farnsworth KD, Dinsmore WW. Persistent sexual dysfunction in genitourinary medicine clinic attendees induced by selective serotonin reuptake inhibitors. Int J STD & AIDS. 2009;20(1):68–9. Available from: PM:19103903CrossRefGoogle Scholar
  14. 14.
    Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81. Available from: PM:25721705CrossRefGoogle Scholar
  15. 15.
    Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatr. 1996;153(2):151–62. Available from: PM:8561194CrossRefGoogle Scholar
  16. 16.
    Johnstone EC, Crow TJ, Frith CD, Owens DG. The Northwick Park “functional” psychosis study: diagnosis and treatment response. Lancet. 1988;2(8603):119–25. Available from: PM:2899186CrossRefGoogle Scholar
  17. 17.
    Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA. The effect of lithium carbonate on affect, mood, and personality of normal subjects. Arch Gen Psychiatry. 1977a;34(3):346–51. Available from: PM:320956CrossRefGoogle Scholar
  18. 18.
    Judd LL, Hubbard B, Janowsky DS, Huey LY, Takahashi KI. The effect of lithium carbonate on the cognitive functions of normal subjects. Arch Gen Psychiatry. 1977b;34(3):355–7. Available from: PM:320957CrossRefGoogle Scholar
  19. 19.
    Kendler KS, Schaffner KF. The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philos Psychiatry Psychol. 2011;18:41–63.CrossRefGoogle Scholar
  20. 20.
    Mizrahi R, Bagby RM, Zipursky RB, Kapur S. How antipsychotics work: the patients’ perspective. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(5):859–64. Available from: PM:15908094CrossRefGoogle Scholar
  21. 21.
    Moncrieff J. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Disord. 2001;189(5):288–95. Available from: PM:11379971CrossRefGoogle Scholar
  22. 22.
    Moncrieff J. The myth of the chemical cure: a critique of psychiatric drug treatment. Basingstoke: Palgrave Macmillan; 2008.Google Scholar
  23. 23.
    Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv Rev Psychiatry. 2009;17(3):214–25. Available from: PM:19499420CrossRefGoogle Scholar
  24. 24.
    Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoSMed. 2015;12(8):e1001861. Available from: PM:26241954Google Scholar
  25. 25.
    Moncrieff J, Cohen D. Rethinking models of psychotropic drug action. Psychother Psychosom. 2005;74(3):145–53. Available from: PM:15832065CrossRefGoogle Scholar
  26. 26.
    Moncrieff J, Cohen D. Do antidepressants cure or create abnormal brain states? PLoS Med. 2006;3(7):e240. Available from: PM:16724872CrossRefGoogle Scholar
  27. 27.
    Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of internet data. Acta Psychiatr Scand. 2009;120(2):102–11. Available from: PM:19222405.CrossRefGoogle Scholar
  28. 28.
    Moncrieff J, Kirsch I. Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials. 2015;43:60–2. Available from: PM:25979317CrossRefGoogle Scholar
  29. 29.
    Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology. 2002;163(1):42–53. Available from: PM:12185399CrossRefGoogle Scholar
  30. 30.
    Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D. Should psychiatrists be more cautious about the long-term use of antipsychotics? Br J Psychiatry. 2016;209:361–5.CrossRefGoogle Scholar
  31. 31.
    Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1972;26(2):146–53. Available from: PM:4551257CrossRefGoogle Scholar
  32. 32.
    Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982;4(3):173–93. Available from: PM:6127357CrossRefGoogle Scholar
  33. 33.
    Royal College of Psychiatrists. Antidepressants. London: Royal College of Psychiatrists; 2009. Ref type: pamphlet.Google Scholar
  34. 34.
    Sharma T, Guski LS, Freund N, Gotzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. Br Med J. 2016;352:i65. Available from: PM:26819231CrossRefGoogle Scholar
  35. 35.
    Stahl SM. Stahl’s essential psychopharmacology. 4th ed. Cambridge: Cambridge University Press; 2013.Google Scholar
  36. 36.
    Tschanz JT, Rebec GV. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1988;31(3):519–22. Available from: PM:3251235CrossRefGoogle Scholar
  37. 37.
    Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatr. 1991;148(6):714–26. Available from: PM:1674645CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Joanna Moncrieff
    • 1
  1. 1.University College LondonLondonUK

Personalised recommendations